A COMPARATIVE STUDY OF DRUG SUSCEPTIBILITY OF SLOW-GROWING MYCOBACTERIA (M. kansasii and M. xenopi)
Abstract
The broth microdilution method (Sensititre® SlowMyco) allows to obtain quantitative data of the degree of susceptibility/resistance of mycobacteria strains. In the study of the drug sensitivity of M. kansasii and M. xenopi, most cultures of these species were found to be resistant to antituberculosis and to other antibacterial drugs used for the treatment of diseases caused by these non-tuberculosis mycobacteria. However, M. kansasii was more resistant to trimetho-Prim/ sulfamethoxazole and ciprofloxacin, and M. xenopi to ethambutol and ethionamide. It should be emphasized that a significant part (> 10%) of the strains of M. kansasii and M. кopi with intermediate sensitivity to many studied antibacterial drugs, which creates a certain reserve for the use of these drugs in the treatment of mycobacteriosis with a high degree of drug resistance of the pathogen.
About the Authors
M. V. Makarova
ГБУЗ «Московский городской научно-исследовательский центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
D. A. Kudlay
ФГБУ «ГНЦ Институт иммунологии» ФМБА России
Russian Federation
Russian Federation
E. N. Khachaturiants
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
L. D. Guntupova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулёзом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
Yu. D. Mikhailova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
Г. Фрейман
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
V. I. Litvinov
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Андреевская С.Н., Ларионова Е.Е., Смирнова Т.Г. и др. Лекарственная чувствительность медленнорастущих нетуберкулезных микобактерий // Туберкулез и болезни легких. – 2016. – № 4. – С. 43-50.
2. Гунтупова Л.Д., Борисов С.Е., Соловьева И.П. и др. Клинико-морфологическая характеристика микобактериозов легких // Архив патологии. – 2011. – Т. 73. – № 5. – С. 12-16.
3. Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии. – М.: МНПЦБТ. – 2008. – 255 с.
4. Литвинов В.И., Мороз А.М. (титул. ред.) Лабораторные исследования при туберкулезе. – М.: МНПЦБТ. – 2013. – 342 с.
5. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы. – М.: МНПЦБТ. – 2014. – 254 С.
6. Макарова М.В., Крылова Л.Ю., Носова Е.Ю., Литвинов В.И. Характеристика штаммов M. tuberculosis с широкой лекарственной устойчивостью с помощью тест-системы Sensititre MycoTB (предпосылки для внесения корректив в лечение больных туберкулезом с ШЛУ возбудителя) // Туберкулез и социально значимые заболевания. – 2016. – № 2. – С. 38-43.
7. Оттен Т.Ф., Васильев А.В. Микобактериоз. – СПб.: Мед. пресса, 2005. – 224 с.
8. Abuali M. M., Katariwala R., LaBombardi V.J. A comparison of the Sensititre® MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. – Vol. 31. – N. 5. – P. 835-839.
9. Alcaide F., Calatayud L., Santín M., Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii // Antimicrob. Agents. Chemother. – 2004. – Vol. 48. – N. 12. – P. 4562-4565.
10. Alvarez-Uria G. Lung disease caused by nontuberculous mycobacteria // Curr. Opin. Pulm. Med. – 2010. – Vol. 16. – N. 3. – P. 251-256.
11. Babady N., Hall L., Abbenyi A. et al. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and Just-One strips // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 5. – P. 1749-1752.
12. Brode S., Daley C., Marras T. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review // Int. J. Tuberc. Lung. Dis. – 2014. – Vol. 18. – N. 11. – P. 1370-1377.
13. Brown-Elliott B., Griffith D., Wallace R. Diagnosis of nontuberculous mycobacterial infections // J. Clin. Lab. Med. – 2002. – Vol. 22. – P. 911-925.
14. Brown-Elliott B., Wallace R. Infections caused by nontuberculous mycobacteria // In: Principles and Practice of Infectious Disease. (eds. Mandell G.). – 2005. – Vol. 2. – P. 2909-2916.
15. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – P. 545-582.
16. Cavusoglu C., Gurpinar T., Ecemis T. Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by Sensititre RAPMYCO panel // New Microbiol. – 2012. – V. 35. – N. 1. – P. 73-76.
17. Chakravorty S., Lee J., Cho E. et al. Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing // J. Clin. Microbiol. – 2015. – Vol. 53. – N. 1. – P. 43-51.
18. CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard – second edition // CLSI document M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
19. Daley C. Mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 1-22.
20. Deshpande D., Srivastava S., Meek C. et.al. Moxifloxacin pharmaco-kinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection // Antimicrob. Agents. Chemother. – 2010. – Vol. 54. – N. 6. – P. 534-539.
21. Deshpande D., Gumbo T. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium // Future Microbiol. – 2011. – Vol. 6. – N. 4. – P. 433-439.
22. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria // Chest. – 2008. – Vol. 133. – N. 1. – P. 243-251.
23. Griffith D., Aksamit T., Brown-Elliott B. et. al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases // J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 4. – P. 367-416.
24. Guna R., Muñoz C., Domínguez V. et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii // J. Antimicrob. Chemother. – 2005. – Vol. 55. – N. 6. – P. 950-953.
25. Hall L., Jude K. P., Clark S.L. et al. Evaluation of the Sensititre MycoTB Plate for Susceptibility Testing of the Mycobacterium tuberculosis сomplex against First- and Second-Line Agents // J. Clin.Microbiol. – 2012. – Vol. 50. – N. 11. – P. 3732-3734.
26. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections // CRC Press. Boca Raton Ann Arbor Boston. London, 2000. – P. 212.
27. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. in Respir. Crit. Care Med. – 2004. – Vol. 25. – N. 3. – P. 283-295.
28. Hoefsloot W., van Ingen J., Andrejak C. et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study // Eur. Respir. J. – 2013. – Vol. 42. – N. 6. – P. 1604-1613.
29. Horsburgh C., Mason U., Heifets L. et.al. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing // Am. Rev. Respir. Dis. – 1987. – Vol. 135. – N. 2. – P. 418-421.
30. Iseman M. Medical management of pulmonary disease caused by M. avium complex // Clin. Chest. Med. – 2003. – Vol. 23. – P. 633-641.
31. Jenkins P., Campbell I. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five-year follow-up of patients receiving standardised treatment // Respir. Med. – 2003. – Vol. 97. – N. 4. – P. 439-444.
32. Jubulis J., Dionne K., Osterhout G. Mycobacterium tuberculosis resistance in pulmonary TB patients in Cameroon: a phenotypic susceptibility assay // Int. J. Tuberc. Lung. Dis. – 2015. – Vol. 19. – N. 7. – P. 823-827.
33. Lee J, Armstrong D, Ssengooba W. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second – line drugs // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 11-18.
34. Mpagama S., Houpt E., Stroup S. et al. Application of quantitative second-line drug susceptibility at a multidrug-resistant tuberculosis hospital in Tanzania // BMC Infectious Diseases. – 2013. – Vol. 13. – P. 432-441.
35. Park C., Kwon Y. Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease // Tuberc. Respir. Dis. (Seoul). – 2014. – Vol. 77. – N. 4. – P. 161-166.
36. Prevots D., Marras T. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review // Clin. Chest. Med. – 2015. – Vol. 36. – N. 1. – P. 13-34.
37. Stout J., Koh W., Yew W. Update on pulmonary disease due to non-tuberculous mycobacteria // Int. J. Infect. Dis. – 2016. – Vol. 45. – P. 123-134.
38. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin. Microbiol. Infect. – 2009. – Vol. 15. – N. 10. – P. 906-910.
39. van der Werf M., Ködmön C., Katalinić-Janković V. et al. Inventory study of non-tuberculous mycobacteria in the European Union // BMC Infect. Dis. – 2014. – Vol. 14. – P. 62. Supplementary files.
40. van Ingen J. Diagnosis of nontuberculous mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 103-109.
41. van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease // Clin. Chest. Med. – 2015. – Vol. 36. – N. 1. – P. 43-54.
42. Varadi R., Marras T. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review // Int. J. Tuberc. Lung. Dis. – 2009. – Vol. 13. – N. 10. – P. 1210-1218.
43. Woods G. Susceptibility testing for mycobacteria // Clin. Infect. Dis. – 2000. – Vol. 31. – N. 5. – P. 1209-1215.
Review
For citations:
Makarova M.V., Kudlay D.A., Khachaturiants E.N., Guntupova L.D., Mikhailova Yu.D., , Litvinov V.I. A COMPARATIVE STUDY OF DRUG SUSCEPTIBILITY OF SLOW-GROWING MYCOBACTERIA (M. kansasii and M. xenopi). Tuberculosis and socially significant diseases. 2019;(1):25-31. (In Russ.)
Views:
33
Email this article 